Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-21
2007-08-21
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S452000, C536S006500, C536S007100, C536S007200
Reexamination Certificate
active
10492439
ABSTRACT:
A pharmaceutical compound comprising a compound of formula I and a pharmaceutically acceptable 2-amino-1,3-propanediol beside one or more pharmaceutically acceptable excipient(s).
REFERENCES:
patent: 5482965 (1996-01-01), Rajadhyaksha
patent: 6274629 (2001-08-01), Cottens et al.
patent: 0 349 061 (1990-01-01), None
patent: 0 427 680 (1991-05-01), None
patent: 0 627 406 (1994-12-01), None
patent: 0 778 263 (1997-06-01), None
patent: 1 002 792 (2000-05-01), None
patent: 1 050 301 (2000-11-01), None
patent: 2252041 (1992-07-01), None
patent: 94/21642 (1994-09-01), None
patent: 97/14439 (1997-04-01), None
patent: 98/22100 (1998-05-01), None
patent: 01/60345 (2001-08-01), None
patent: 02/056790 (2002-07-01), None
Dumont, “FTY-720 Novartis/Yoshitomi”, Current Opinion in Anti-Inflammatory and Immunomodulatory Investigational Drugs, vol. 2, No. 4, pp. 314-331 (2000).
Fukuda et al., “Effect of FTY720 on Immunoregulation in Concordant Xenotransplantation”, Transpl. Int., vol. 11, Suppl. 1, pp. S461-S464 (1998).
Furukawa et al., “Prolongation of Canine Liver Allograft Survival by a Novel Immunosuppressant, FTY720: Effect of Monotherapy and Combined Treatment with Conventional Drugs”, Transplantation, vol. 69, No. 2, pp. 235-?? (2000).
Hoshino et al., “FTY720, a Novel Immunosuppressant, Shows a Synergistic Effect in Combination with FK 506 in Rat Allograft Models”, Transplantation Proceedings, vol. 31, pp. 1224-1226 (1999).
Kahan et al., “Current Immunosuppressant Regimens: Considerations for Critical Care”, Curr. Opin. Crit. Care, vol. 7, pp. 242-250 (2001).
Kelly et al., “Review: Metabolism of Immunosuppressant Drugs”, Current Drug Metabolism, vol. 3, pp. 275-287 (2002).
Miyata et al., “Prolongation of Concordant Xenograft Survival by Treatment With FTY720”, Transplantation Proceedings, vol. 30, pp. 4163-4165 (1998).
Morel, “mTOR and FTY 720 Inhibitors”, Presse Med, vol. 30, No. 24, pp. 35-37 (2001)—Abstract Needed.
Nikolova et al., “Efficacy of SDZ RAD compared with CsA Monotherapy and Combined RAD/FTY720 Treatment in a Murine Cardiac Allotransplantation Model”, Transplant Immunology, vol. 9, pp. 43-49 (2001).
Seiichi, “Development of Immunological Adjustment Technology for Transplantation”, Kanmin Kyodo Purojekuto Kenkyu Hokoku, pp. 107-112 (1997)—JICST-EPlus Abstract No. 970791088.
Tamura, “Combination Effect of FTY720 and Tacrolimus in Rat Liver Transplantation”, Keio Igaku, vol. 79, No. 2, pp. T273-T282 (2002)—HCAPLUS Abstract No. 2002:327475.
Tamura et al., “Immunosuppressive Therapy Using FTY720 Combined with Tacrolimus in Rat Liver Transplantation”, Surgery, vol. 127, pp. 47-54 (2000).
Tamura et al., “Combination Effect of Tacrolimus and FTY720 in Liver Transplantation in Rats”, Transplantation Proceedings, vol. 31, pp. 2785-2786 (1999).
Xu et al., “Effect of Peritransplant FTY720 Alone or in Combination with Post-Transplant Tacrolimus in a Rat Model of Cardiac Allotransplantation”, Transpl. Int., vol. 11, pp. 288-294 (1998).
Xu et al., “Effect of Peritransplant FTY720 Alone or in Combination with Posttransplant FK 506 in a Rat Model of Cardiac Allotransplantation”, Transplantation Proceedings, vol. 29, pp. 2964-2966 (1997).
Hartley Michael G.
Houghton Gregory C.
Novartis AG
Rogers James W.
LandOfFree
Macrolides containing pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrolides containing pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrolides containing pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862406